2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Locatelli, F. Articles by Pozzoni, P. Search for Related Content PubMed PubMed Citation Articles by Locatelli, F. Articles by Pozzoni, P.

Anemia and Cardiovascular Risk: The Lesson of the CREATE Trial

Francesco Locatelli^*, Lucia Del Vecchio and Pietro Pozzoni^*

^* Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, and Department of Hypertension and Preventive Nephrology, IRCCS Policlinico Multimedica, Sesto San Giovanni, Milan, Italy

Address correspondence to: Prof. Francesco Locatelli, Department of Nephrology and Dialysis, A. Manzoni Hospital, Via Dell’Eremo 9, 23900 Lecco, Italy. Phone: +39-0341-489862; Fax: +39-0341-489860; E-mail: nefrologia{at}ospedale.lecco.it

Anemia has received increasing attention as an independent cardiovascular risk factor in patients with chronic kidney disease (CKD); a number of studies have highlighted its clear relationship with CKD mortality, because its impact on cardiac function leads to the development of left ventricular hypertrophy. However, despite the association between higher hemoglobin levels and better outcomes, a number of clinical studies have failed to demonstrate that fully correcting anemia has a positive effect on morbidity and mortality in patients with CKD. The Cardiovascular Reduction Early Anemia Treatment Epoetin (CREATE) study was designed from the hypothesis that, as anemia develops early in the course of CKD and nearly at the same time as cardiovascular disease, its earlier correction may provide better protection against the development of cardiovascular abnormalities. This randomized, multicenter, open-label, parallel-group trial involved 603 patients who had moderate anemia (hemoglobin 11 to 12.5 g/dl) and stage 3 to 4 CKD (estimated GFR 15 to 35 ml/min) and were randomly assigned to attain complete or partial anemia correction. The final results are due to be published within a few months, but the preliminary analyses do not show that complete anemia correction leads to any cardiovascular advantage, although the cardiovascular event rate was half that expected, possibly as a result of patient selection, trial effect, and improved medical care. The baseline findings also indicated that the burden of cardiovascular disease already is very high even in relatively early stages of CKD.

This article has been cited by other articles:

				S. D. Anker and R. Toto Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients NDT Plus, January 1, 2009; 2(suppl_1): i3 - i8. [Abstract] [Full Text] [PDF]

				X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673